Plasmodium falciparum has become resistant to artemisinin
Artemisinin is the first line treatment of uncomplicated falciparum malaria in areas where malaria is endemic, but evidence is emerging that the parasite is becoming resistant to this drug at the Thai-Cambodian border. This is the site where, in the 1950s and 1960s, resistance to chloroquine and sulfadoxine-pyrimethamine originated, before it spread across Asia and to Africa, contributing to millions of deaths from malaria⇑.
After previous reports of possible artemisinin resistance, two open label randomised trials of 40 patients each, one in Pailin, western Cambodia, and the other in Wang Pha, northwestern Thailand, compared the efficacies of two treatments for uncomplicated falciparum malaria—oral artesunate for seven days, and artesunate for three days followed by two doses of mefloquine.
The trials showed that in vivo susceptibility to artesunate is reduced in Plasmodium falciparum found in Cambodia compared with parasites from Thailand. The median parasite clearance time was 48 hours in Thailand, compared with 84 hours in Cambodia. Rates of recrudescence in the monotherapy and combined groups, respectively, were two of 20 patients and one of 20 in Thailand, and six of 20 and one of 20 in Cambodia. The difference could not be explained by age, pharmacokinetics, in vitro sensitivity tests, or molecular correlates of P falciparum drug resistance.
The authors call for urgent containment measures to limit the spread of resistant parasites.
New approach shows promise for a vaccine against malaria
Immunity against malaria is difficult to achieve, either by natural exposure or by vaccination, and we still don’t know what precisely constitutes antimalarial immunity in humans⇑. Previous attempts to develop a vaccine revolved around the use of irradiated infected mosquitoes; however, a minimum of 1000 mosquito bites over five or more immunisation sessions is needed to induce immunity in volunteers—clearly an inappropriate method for routine use. Some hope comes from the development of subunit …
Sign in
Personal subscribers, sign in here:
Article access
Article access for 1 day
Purchase this article for £20 $30 €32*
The PDF version can be downloaded as your personal record
CiteULike
Connotea
Del.icio.us
Digg
Facebook
Reddit
Technorati
Twitter
Stumbleupon
Rapid responses
Latest Responses
The decline in the breast cancer incidence is 1.2% and it is not significant.
Published 10 February 2012
'twas ever thus
Published 10 February 2012
The value of historic human remains
Published 10 February 2012
In Praise of British Literature
Published 10 February 2012
Is real shared decision making possible?
Published 10 February 2012
Most responses
Does anyone understand the government’s plan for the NHS? (17 responses)
Published 17 Jan 2012
Bad medicine: medical nutrition (15 responses)
Published 18 Jan 2012
Shared decision making: really putting patients at the centre of healthcare (7 responses)
Published 27 Jan 2012
Why legislation is necessary for my health reforms (7 responses)
Published 1 Feb 2012
Search for evidence goes on (5 responses)
Published 17 Jan 2012